Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies
This is the report of an individual patient data meta-analysis of all patients included in the phase 3 BCAT and PRODIGE-12 trials of adjuvant gemcitabine-based chemotherapy for biliary tract cancer (BTC). 212 vs 207 patients were randomized in the gemcitabine-based chemotherapy versus observation arms. There was no difference in RFS (log-rank p=0.45; HR=0.91; 95%CI 0.71-1.16; p=0.46). RFS rates at 5 years were 40.8% (95%CI 33.9%-47.5%) for gemcitabine-based chemotherapy versus 36.6% (95%CI 29.8%-43.4%) for observation. There was no difference in OS (log-rank p=0.83; HR=1.03; 95%CI 0.78-1.35; p=0.85). OS rates at 5 years were 50.5% (95%CI 43.1%-57.4%) for gemcitabine-based chemotherapy versus 49.3% (95%CI 41.6%-56.5%) for observation. This analysis confirms that gemcitabine-based chemotherapy should not be used as an adjuvant treatment for BTC.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.